Institutional Repository of Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model | |
Li, Yuan1,2; Du, Yang3![]() ![]() | |
Source Publication | BMC CANCER
![]() |
ISSN | 1471-2407 |
2018-06-19 | |
Volume | 18Pages:7 |
Corresponding Author | Jin, Zhengyu(jin_zhengyu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn) |
Abstract | Background: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model. Methods: The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment. Results: The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity. Conclusion: Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment. |
Keyword | PD-1 Zoledronic acid Breast cancer Therapy Checkpoint inhibitior |
DOI | 10.1186/s12885-018-4412-8 |
WOS Keyword | CHECKPOINT INHIBITORS ; PHASE-3 TRIAL ; OPEN-LABEL ; METASTASES ; ANTIBODY ; THERAPY ; LIGAND ; SAFETY |
Indexed By | SCI |
Language | 英语 |
Funding Project | National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61231004] ; National Natural Science Foundation of China[81171390] ; Key Projects in the National Science & Technology Pillar Program[2012BAI23B06] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science & Technology Commission[Z161100002616022] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61231004] ; National Natural Science Foundation of China[81171390] ; Key Projects in the National Science & Technology Pillar Program[2012BAI23B06] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science & Technology Commission[Z161100002616022] |
Funding Organization | National Natural Science Foundation of China ; Key Projects in the National Science & Technology Pillar Program ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science & Technology Commission |
WOS Research Area | Oncology |
WOS Subject | Oncology |
WOS ID | WOS:000435892200004 |
Publisher | BIOMED CENTRAL LTD |
Citation statistics | |
Document Type | 期刊论文 |
Identifier | http://ir.ia.ac.cn/handle/173211/23180 |
Collection | 中国科学院分子影像重点实验室 |
Corresponding Author | Jin, Zhengyu; Tian, Jie |
Affiliation | 1.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Radiol, 1 Shuaifuyuan, Beijing 100730, Peoples R China 2.Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China 3.Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, Key Lab Mol Imaging CAS, 95 ZhongGuanCun East Rd, Beijing 100190, Peoples R China |
Corresponding Author Affilication | Institute of Automation, Chinese Academy of Sciences |
Recommended Citation GB/T 7714 | Li, Yuan,Du, Yang,Sun, Ting,et al. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model[J]. BMC CANCER,2018,18:7. |
APA | Li, Yuan,Du, Yang,Sun, Ting,Xue, Huadan,Jin, Zhengyu,&Tian, Jie.(2018).PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.BMC CANCER,18,7. |
MLA | Li, Yuan,et al."PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model".BMC CANCER 18(2018):7. |
Files in This Item: | Download All | |||||
File Name/Size | DocType | Version | Access | License | ||
LY_BMC_Cancer_2018.p(4369KB) | 期刊论文 | 作者接受稿 | 开放获取 | CC BY-NC-SA | View Download |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment